# Sources — Lili Boulanger

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Bibliothèque nationale de France. Authority record "Boulanger, Lili (1893-1918)." Supports birth on 1893-08-21 in Paris, 9th arrondissement; death on 1918-03-15 at Mézy-sur-Seine (Yvelines); "Compositrice. - Soeur de Nadia Boulanger (1887-1979)"; "Reçoit le Grand prix de Rome de composition musicale en 1913"; and the civil-register given names "Marie-Juliette Olga." https://catalogue.bnf.fr/ark:/12148/cb13891732m
2. "Boulanger, Lili (1893–1918)." *Women in World History: A Biographical Encyclopedia* (Gale), on Encyclopedia.com. Supports "Born Juliette Marie Olga Boulanger on August 21, 1893, in Paris"; health "poor from birth"; the May 1913 final round, in which she was the only woman of five contestants; *Faust et Hélène*; the vote of the Académie des Beaux-Arts making her the first woman to win the Premier Grand Prix de Rome in music; and that she "died of tuberculosis on March 15, 1918, in Paris." https://www.encyclopedia.com/women/encyclopedias-almanacs-transcripts-and-maps/boulanger-lili-1893-1918
3. Bru Zane Mediabase (Palazzetto Bru Zane, Centre de musique romantique française). "Boulanger, Lili." Supports that "she caught pneumonia when she was two" and "remained sickly until the end of her life"; the Premier Prix de Rome in 1913 for *Faust et Hélène*, the first woman to win since 1803; leaving for the Villa Medici in 1914; leaving Rome rapidly for Nice when the war broke out, where she composed *Clairières dans le ciel*; a second stay in Rome in 1916; and death "of tuberculosis in the Paris area" in March 1918. https://www.bruzanemediabase.com/en/exploration/artists/boulanger-lili
4. Holland-Barry A. "Lili Boulanger (21 August 1893–15 March 1918)." RISM (Répertoire International des Sources Musicales), March 15, 2018. Supports bronchial pneumonia in 1895 at two, "from which her immune system never fully recovered"; "episodes of intestinal tuberculosis, now known as Crohn's Disease"; and the 1913 Prix de Rome for *Faust et Hélène*. https://rism.info/musical_anniversaries/2018/03/15/lili-boulanger-21-august-189315-march-1918.html
5. Ueda Y. "Boulanger, Lili." PTNA Piano Encyclopedia, an article drawn from Jérôme Spycket's biography *À la recherche de Lili Boulanger* (Fayard, 2004), which was not read directly. Supports that early in 1915, back in Paris, she had headaches, loss of appetite, and fever, followed by symptoms resembling colitis and appendicitis, and spent much of her time in bed while composing; the Franco-American Committee of the Conservatoire founded with her sister; Rome from February to June 1916; an operation on July 30, 1917, not named; evacuation to a house in Mézy-sur-Seine; and a description of her illness as Crohn disease. https://enc.piano.or.jp/en/persons/1432
6. Coduti CL. "Who Was Lili Boulanger? The Story Behind *Soir sur la Plaine*." Pacific Chorale, May 5, 2026. Supports "a severe case of bronchial pneumonia" at two that "nearly proved fatal," and "a chronic intestinal condition diagnosed at the time as intestinal tuberculosis, or what is known today as Crohn's disease." https://www.pacificchorale.org/lili-boulanger-soir-sur-la-plaine
7. Graham D. "Lili Boulanger: in her tragically short life, she helped shape 20th-century music." *BBC Music Magazine* (classical-music.com), February 9, 2021. Supports that she suffered from what the author calls Crohn disease; an unauthorized return to Paris in the summer of 1914; and that, unable to hold a pen, she dictated her music to her sister. https://www.classical-music.com/features/composers/boulanger-lili
8. HISTMED Master Roster v3. Internal project source. Its claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. Lichtenstein GR, et al. "ACG Clinical Guideline: Management of Crohn's Disease in Adults." *Am J Gastroenterol* 2025;120(6):1225–1264. PMID 40701562. The 2025 edition replaces the 2018 guideline. Abstract read; it advocates shared decision-making. https://pubmed.ncbi.nlm.nih.gov/40701562/
2. Feuerstein JD, et al. "AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease." *Gastroenterology* 2021. PMID 34051983. Early advanced therapy for moderate to severe disease. https://pubmed.ncbi.nlm.nih.gov/34051983/
3. Gordon H, et al. "ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment." *J Crohns Colitis* 2024;18(10):1531–1555. PMID 38877997. https://pubmed.ncbi.nlm.nih.gov/38877997/
4. Maaser C, et al. "ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1." *J Crohns Colitis* 2019. PMID 30137275. Ileocolonoscopy with biopsies and cross-sectional imaging at diagnosis. https://pubmed.ncbi.nlm.nih.gov/30137275/
5. "ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease." *J Crohns Colitis* 2026. PMID 42417116 (this 2026 edition replaces the 2021 edition, PMID 33730753). Tuberculosis, hepatitis B, and vaccine preparation before immunosuppression. https://pubmed.ncbi.nlm.nih.gov/42417116/
6. "ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease." *Am J Gastroenterol* 2025;120:1447–1473. PMID 40701559. Vaccines, bone health, cervical and skin cancer prevention, mood screening, and smoking. https://pubmed.ncbi.nlm.nih.gov/40701559/
7. Turner D, et al. "STRIDE-II." *Gastroenterology* 2021;160:1570–1583. PMID 33359090. Treat-to-target goals: clinical response, CRP and calprotectin normalization, and endoscopic healing. https://pubmed.ncbi.nlm.nih.gov/33359090/
8. "Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease." *Clin Gastroenterol Hepatol* 2025;23:S1–S60. PMID 40874901. https://pubmed.ncbi.nlm.nih.gov/40874901/
9. SKYRIZI (risankizumab-rzaa) prescribing information, DailyMed (label published November 2026). Crohn disease induction 600 mg intravenously at weeks 0, 4, and 8; maintenance 180 or 360 mg subcutaneously at week 12 and every 8 weeks; liver enzymes and bilirubin at baseline and during induction up to at least week 12; consider tuberculosis evaluation before starting; avoid live vaccines; insufficient pregnancy data. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858
10. Shane AL, et al. "2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea." *Clin Infect Dis* 2017;65(12):e45–e80. PMID 29053792. Used at the sick visit. https://pubmed.ncbi.nlm.nih.gov/29053792/
11. Centers for Disease Control and Prevention. Adult Immunization Schedule by Medical Condition and Other Indication (https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html) and by Age (https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html).
12. Medicare Preventive Services reference (Aether Forge, 2026), the preventive visit template (https://patrickrutledge.github.io/preventative_services/); U.S. Preventive Services Task Force A and B recommendations and cervical cancer screening (2018) (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations). The CMID has no inflammatory bowel disease monograph, so the specialty guidelines above set the monitoring protocol.

## Editorial resolutions

- **The historical diagnosis is not settled.** Her chronic intestinal illness is described in reference works and essays as intestinal tuberculosis, and several give tuberculosis as the cause of death (sources 2, 3, 4, 6); later writers call it Crohn disease (sources 4, 5, 6, 7), a disease not described as a distinct entity until long after her death. No peer-reviewed article proposing either diagnosis was found (a PubMed search returned none), and no test from her lifetime is reported. Both are graded **R** with certainty disputed. The modern problem is linked to the documented early-1915 symptoms (**D**) and to both interpretations (**R**), with placement both_with_link. It is marked confirmed only because endoscopy, histology, imaging, and negative tuberculosis tests confirm it within the synthetic episode; this does not assert that she had Crohn disease. The synthetic workup deliberately excludes intestinal tuberculosis, the conflicting historical diagnosis, before any immunosuppression.
- **Childhood pneumonia and immunity.** Pneumonia at about two (1895) and frail health afterwards are documented (**D**). The usual account that it weakened her immune system is a biographical interpretation, graded **R** possible. One fetched source instead attributes her low immunity to inflammatory bowel disease.
- **Names and places.** The national library authority record gives the civil-register names Marie-Juliette Olga and death at Mézy-sur-Seine. One reference biography gives "Juliette Marie Olga" and death in Paris, and another gives "Julie-Marie Olga" and "the Paris area." The authority record is preferred, the alternatives are recorded in the claims, and the alias is Marie-Juliette Olga Boulanger.
- **Sources not read.** Grove Music Online, Annegret Fauser's work, and Jérôme Spycket's biography were not accessible. Spycket is used only as summarized in an encyclopedia article (source 5); claims resting on it alone are graded **D** with certainty probable. The Centre international Nadia et Lili Boulanger website could not be reached.
- **Index age and whereabouts.** The index visit on January 19, 2026 maps to January 19, 1915, when she was 21 and living in Paris, early in the year when headaches, loss of appetite, fever, and colitis-like symptoms are documented (source 5). The synthetic date of birth is August 21, 2004 (shift 111 years). The other visits (January 28, March 2, April 13, April 27, August 3, and October 19, 2026) map to the same days of 1915; the fetched sources place her in Paris in 1915 and say nothing of a journey that year, and no visit contradicts a documented event. Her 1914 travel to Rome and Nice falls before the index date. All visits fall within her lifetime.
- **Choice of therapy.** Decided: risankizumab, an interleukin-23 inhibitor, as early advanced therapy for moderate to severe ileocolonic disease (Montreal A2 L3 B1, SES-CD 14), with a short prednisone bridge. The alternatives (infliximab with azathioprine, adalimumab, ustekinumab, vedolizumab) were offered in the consultation. The reasons recorded: efficacy in ileocolonic disease, no need for an immunomodulator, a low rate of serious infection after tuberculosis had been excluded, and home injection that suits her work. The trade-off, recorded as hers to accept, is more limited pregnancy data than for anti-TNF drugs; the pregnancy counseling says the options will be reviewed before any planned pregnancy. The AGA 2021 guideline predates risankizumab's approval for Crohn disease; the ACG 2025 and ECCO 2024 guidelines and the label cover it.
- **Tuberculosis exclusion.** Negative interferon-gamma release assay, normal chest X-ray, small non-caseating granulomas, negative acid-fast stain and TB PCR, and a mycobacterial culture with no growth at five weeks and negative at six. The prednisone bridge and risankizumab began after the first results and before the final culture; the consultation records this as reasonable with the culture to be reviewed, and it was.
- **Focused visits.** The four chronic-care follow-ups (diagnosis, week 4, week 12, and six months) are documented as focused visits on the ACG 2025, AGA 2021, and ECCO 2024 Crohn disease guidelines, the ECCO infection guideline, the ACG preventive care guideline, STRIDE-II, and the risankizumab label (the CMID has no inflammatory bowel disease monograph). One protocol deviation is recorded: the hepatitis B surface antibody check due one to two months after the booster was left off the week-4 blood tests. It was drawn at week 12 (86 mIU/mL, protective), so no harm resulted, and the corrective action is recorded. The week-8 liver tests, drawn at the infusion center, are reported in prose and are not observations; so are the interferon-gamma release assay, the infection serologies, the stool tests, the mycobacterial culture, and the anti-HBs result, which are qualitative. The Harvey-Bradshaw Index and SES-CD have no LOINC code and are given in note text.
- **Consultation.** The inflammatory bowel disease referral and the consultation by Thaddeus Nwankwo-Delacroix, MD (a fictional consultant), on the day of the second visit, are **S**. The consultant answers the six referral questions with what the record shows happened afterwards: Crohn disease confirmed and tuberculosis excluded, with the culture reviewed; Montreal classification and high risk; risankizumab with a prednisone bridge; the vaccines, with no live vaccine needed; intravenous iron, vitamin D, calcium, a dietitian, and DXA; and treat-to-target monitoring, with pregnancy counseling.
- **Sick visit.** An unscheduled sick visit on April 13, 2026 (true frame April 13, 1915) for norovirus gastroenteritis ten weeks into risankizumab. It teaches the distinction between an infection and a Crohn flare, stool testing for *Clostridioides difficile*, and deferring calprotectin until recovery. It does not echo a documented illness.
- **Preventive visit.** An adult preventive visit (age 22, so `preventive_adult`) on October 19, 2026 (true frame October 19, 1915). Synthetic judgment calls: the HPV series in adolescence; the first cervical cytology at this visit, with no result; COVID-19 vaccination at a pharmacy, not recorded as given; advance care planning names no real person as her health care agent.
- **Relatives and real people.** Her sister appears only in documented claims (her dates and profession, the wartime committee, and dictation in her last illness); her mother does not appear. No relative, teacher, or companion is the source of any modern statement, decision, or health fact. The modern social history gives her a shared apartment and unnamed friends. The engagement mentioned in one source is not used.
- **Family history.** No family medical history is recorded; none is synthesized.
- **Presenting concern.** The intake documents list the presenting concern (PRB-002: abdominal pain, diarrhea, fevers, and weight loss) rather than Crohn disease, which is recorded from the diagnosis visit; the presenting concern is resolved, superseded by the diagnosis, from that visit on. Iron deficiency anemia and vitamin D deficiency resolve at week 12 and malnutrition at six months.
- Boulanger died in 1918, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
